Camonsertib

Phase 2Small molecule

Camonsertib is one of 42 small molecule programs targeting Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Recruiting

Solid TumorActive, not recruiting

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Phase 1

Recruiting

Solid TumorPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Camonsertib

Roche

Phase 2

1 8

Navmi

SSummit Therapeutics

Preclinical

1 9

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

NCT07156227

Q3 2032

Phase 2Active, not recruiting

Solid Tumor

NCT04589845

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03337698·314 enrolled

Solid Tumor1 trial

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04589845·920 enrolled

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07156227·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Camonsertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camonsertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camonsertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

Camonsertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2032

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Solid Tumor1 trial

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

References

Drug Info

Quick Facts

Related News